Background Type 2 diabetes is a recognized risk factor for the development of cardiovascular disease. Fenofibrate and curcumin were found to be effective in improving hyperlipidemia in patients with diabetes. This study aimed to evaluate the effect of adding fenofibrate versus curcumin on weight, glycemic status, lipids profile, high-sensitivity C-reactive protein (hs-CRP), fetuin-A, and sirtuin 1 in patients with type 2 diabetes treated with glimepiride. Method In a double-blind, randomized control trial, 60 patients with type 2 diabetes mellitus were randomly assigned into three groups: Group I was given placebo; Group II curcumin 1100 mg; Group III fenofibrate 160 mg (each administered orally once daily) to ongoing glimepiride 4 mg therapy administered orally once daily for three months. Inclusion criteria were as follows: patients aged 35–70 years, those with uncontrolled type 2 diabetes, hyperlipidemia, and those treated with glimepiride 4 mg. Exclusion criteria were as follows: other types of diabetes, pregnancy, abnormal liver or kidney function tests, using other anti-diabetes medications, and non-adherence to medications. At baseline and after three months of intervention, anthropometric measurements were measured, and blood samples were collected for biochemical analysis of blood glucose, glycated hemoglobin (HbA1c), lipid profile, hs-CRP, fetuin-A, and sirtuin 1. Paired t-test and one-way ANOVA were used for normally distributed data. However, the Wilcoxon signed-rank and the Kruskal–Wallis tests were used to analyze non-normally distributed data. Results Three months after the intervention, when the three groups were compared, no significant differences were found regarding weight, body mass index, fasting blood glucose, two-hour postprandial glucose (2 h-PPG), and HbA1c (p > 0.05). Compared to placebo, significant decreases were observed in total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), very-low-density lipoprotein cholesterol (VLDL-C), coronary risk index (CRI), atherogenic index (AI), and hs-CRP and increasing sirtuin 1 in the fenofibrate (p < 0.001) and curcumin (p < 0.05) groups. High-density lipoprotein cholesterol (HDL-C) levels in the fenofibrate group were found to be significantly higher than in the placebo group (p < 0.001). Furthermore, when compared to curcumin, fenofibrate significantly reduced waist circumferences and fetuin-A and increased sirtuin 1 (p < 0.05). Conclusion Both fenofibrate and curcumin are effective at decreasing lipid profiles and improving inflammatory markers in patients with type 2 diabetes. Fenofibrate might have a superior effect in reducing waist circumference, decreasing fetuin-A, and increasing sirtuin 1. Trial registration This trial was registered (August 27, 2020) on clinical trial.gov with an identification code NCT04528212. <a href="https://classic.clinicaltrials.gov/ct2/show/NCT04528212">https://www.clinicaltrials.gov/study/NCT04528212</a>. Graphical Abstract

Effect of adding fenofibrate versus curcumin to glimepiride in patients with type 2 diabetes: a randomized controlled trial

期刊论文
出版模式：

开放获取
发表日期：

2025年6月6日

查看全文

Eman M. Nada,
Nashwa M. El-Gharbawy,
Haidy Abbas,
Rehab H. Werida

摘要

Background

Type 2 diabetes is a recognized risk factor for the development of cardiovascular disease. Fenofibrate and curcumin were found to be effective in improving hyperlipidemia in patients with diabetes. This study aimed to evaluate the effect of adding fenofibrate versus curcumin on weight, glycemic status, lipids profile, high-sensitivity C-reactive protein (hs-CRP), fetuin-A, and sirtuin 1 in patients with type 2 diabetes treated with glimepiride.

Method

In a double-blind, randomized control trial, 60 patients with type 2 diabetes mellitus were randomly assigned into three groups: Group I was given placebo; Group II curcumin 1100 mg; Group III fenofibrate 160 mg (each administered orally once daily) to ongoing glimepiride 4 mg therapy administered orally once daily for three months. Inclusion criteria were as follows: patients aged 35–70 years, those with uncontrolled type 2 diabetes, hyperlipidemia, and those treated with glimepiride 4 mg. Exclusion criteria were as follows: other types of diabetes, pregnancy, abnormal liver or kidney function tests, using other anti-diabetes medications, and non-adherence to medications. At baseline and after three months of intervention, anthropometric measurements were measured, and blood samples were collected for biochemical analysis of blood glucose, glycated hemoglobin (HbA1c), lipid profile, hs-CRP, fetuin-A, and sirtuin 1. Paired t-test and one-way ANOVA were used for normally distributed data. However, the Wilcoxon signed-rank and the Kruskal–Wallis tests were used to analyze non-normally distributed data.

Results

Three months after the intervention, when the three groups were compared, no significant differences were found regarding weight, body mass index, fasting blood glucose, two-hour postprandial glucose (2 h-PPG), and HbA1c (p > 0.05). Compared to placebo, significant decreases were observed in total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), very-low-density lipoprotein cholesterol (VLDL-C), coronary risk index (CRI), atherogenic index (AI), and hs-CRP and increasing sirtuin 1 in the fenofibrate (p < 0.001) and curcumin (p < 0.05) groups. High-density lipoprotein cholesterol (HDL-C) levels in the fenofibrate group were found to be significantly higher than in the placebo group (p < 0.001). Furthermore, when compared to curcumin, fenofibrate significantly reduced waist circumferences and fetuin-A and increased sirtuin 1 (p < 0.05).

Conclusion

Both fenofibrate and curcumin are effective at decreasing lipid profiles and improving inflammatory markers in patients with type 2 diabetes. Fenofibrate might have a superior effect in reducing waist circumference, decreasing fetuin-A, and increasing sirtuin 1.

Trial registration

This trial was registered (August 27, 2020) on clinical trial.gov with an identification code NCT04528212. https://www.clinicaltrials.gov/study/NCT04528212.

Graphical Abstract